There is extensive literature on in vivo studies with cordycepin, but these studies were generally conducted without validation of the various formulations, especially in terms of the solubility of cordycepin in the dosing vehicles used. Cordycepin is a promising drug candidate in multiple therapeutic areas, and there is a growing interest in studies aimed at assessing the pharmacological activity of this compound in relevant animal disease models. It is likely that many reported in vivo studies used formulations in which cordycepin was incompletely soluble. This can potentially confound the interpretation of pharmacokinetics and efficacy results. Furthermore, the presence of particles in intravenously administered suspension can cause adverse effects and should be avoided. Here, we present the results from our development of simple and readily applicable formulations of cordycepin based on quantitative solubility assessment. Homogeneous solutions of cordycepin were prepared in phosphate-buffered saline (PBS) at different pH levels, suitable as formulations for both intravenously and oral administration. For the purpose of high-dose oral administration, we also developed propylene glycol (PPG)-based vehicles in which cordycepin is completely soluble. The stability of the newly developed formulations was also assessed, as well as the feasibility of their sterilisation by filtration. Additionally, an HPLC-UV method for the determination of cordycepin in the formulations, which may also be useful for other purposes, was developed and validated. Our study could provide useful information for improvement of future preclinical and clinical studies involving cordycepin.
INTRODUCTION
Cordycepin (3′-deoxyadenosine) is a nucleoside that differs from adenosine by the absence of the 3′-hydroxyl group. It is the main therapeutically active component in extracts of the insect fungus Cordyceps militaris, which is widely used in traditional medicines of the Far East [1] [2] [3] . The therapeutic potential of cordycepin has been recognised for a wide range of applications and was demonstrated in numerous studies [4] . Proposed pharmacological activities of cordycepin include anti-microbial [4] , anti-tumour [5] [6] [7] [8] , antimutagenic [9] , anti-metastatic [1, 10] , anti-angiogenesis [11] , anti-fungal [12] , anti-diabetic [8, 13] , anti-inflammatory [8, [13] [14] [15] [16] [17] , anti-platelet aggregation [18] , immunomodulatory [19, 20] , hypoglycaemic [21] and anti-herpes [22] effects. The molecular mechanisms of action of cordycepin are not completely understood. However, like many natural products, cordycepin interacts with multiple biological processes, many of which remain to be investigated in detail [2] .
Based on diverse in vitro studies, in vivo preclinical research have been conducted for various indications including cancer [23, 24] , cancer metastasis [25] , vascular disorders [26] , neurodegeneration [27, 28] , fungal infection [12] , osteoporosis [29, 30] , osteogenesis [31] , hyperlipidaemia [32] , hyperglycaemia [21] , viral infections [33] , steroidogenesis [34] , allergy [35] , central nervous system disorders [36, 37] , amongst others [38] [39] [40] (Table I) . Moreover, further studies are anticipated on the pharmacological modes of action and clinical efficacy of cordycepin.
From the many in vivo experiments reported that involved cordycepin, it is noted that a substantial range of doses, and therefore a wide range of concentrations of cordycepin in different dosing vehicles, were used in these studies (Table I) . However, the solubility of cordycepin in water or other dosing vehicles used in these studies has not been reported as far as we can ascertain. Moreover, reports of such studies often do not indicate whether cordycepin formulations at the time of administration were actual homogeneous solutions or merely suspensions. If a formulation is administered orally or intraperitoneally as a suspension, factors such as dissolution and solubilisation could complicate interpretation of the results [41] . Moreover, if a formulation for intravenous administration is a suspension rather than a solution, acute adverse effects can occur, especially if the suspension contains large particles. Such adverse effects can include embolism of blood vessels and inflammation [42] [43] [44] [45] .
Therefore, in this study, simple and readily applicable formulations of cordycepin were developed based on quantitative solubility assessment. Homogeneous solutions of cordycepin were prepared in phosphate-buffered saline (PBS) at different pH levels, yielding formulations that can be administered both intravenously and orally. A propylene glycol (PPG)-based formulation for higher concentration of oral cordycepin administration was also developed. Stability and sterilisation studies for the formulations developed were also carried out.
MATERIALS AND METHODS

Materials
Cordycepin was purchased from Carbosynth Ltd. (Berkshire, UK). Adenosine and Dulbecco's PBS were obtained from Sigma (Gillingham, UK). Water for injection was purchased from Gibco (Paisley, UK), and normal saline was from Baxter (Berkshire, UK). Costar Spin-X centrifuge tubes and propylene glycol were purchased from Fisher Scientific (Loughborough, UK). Sartorius Minisart syringe filters were obtained from Scientific Laboratory Supplies Ltd. (Nottingham, UK). All solvents used in the study were HPLC grade or higher.
Solubility Assay
To assess the solubility of cordycepin in water for injection, normal saline, pH 4.0 PBS, pH 4.5 PBS and pH 5.0 PBS, saturated suspensions of cordycepin were prepared (15 mg of cordycepin per millilitre of solvent). The pH of the formulations in PBS was readjusted using HCl after dissolving cordycepin powder, to readjust the effect of solubilised cordycepin itself on the pH of the formulation. The test suspensions were contained in glass vials and were mixed using a vial roller, overnight at room temperature. The test suspensions were then filtered using Costar Spin-X centrifuge tubes (cellulose acetate, 0.22-μm pore size) by centrifugation at 2400×g for 5 min at room temperature (Heraeus Fresco 17 Centrifuge, Thermo Electron, MA, USA). The filtrate was analysed for the concentration of cordycepin. Solubility of cordyepin in PPG was assessed by preparing saturated suspensions at 20 mg of cordycepin per millilitre of solvent and sonicating for 15 min. The test suspensions were filtered using the method described above, and the filtrates were analysed for cordycepin concentrations. The assay was conducted in quadruplicate. 
Formulation Preparation
Formulations of cordycepin were prepared based on PBS or PPG. For PBS-based formulations, the pH of PBS was adjusted to 4.0, 4.5 and 5.0 using NaOH or HCl prior to addition of cordycepin. PBS-based formulations were prepared by dissolving cordycepin in PBS at pH 4.0, 4.5 and 5.0 at concentrations of 5.5, 4.5 and 3.0 mg/mL, respectively. The formulations were vortex mixed, and the pH of each formulation was then adjusted to its initial pH using HCl to account for the effect of solubilised cordycepin on the pH of the solution. The vortex mix and pH readjustment steps were repeated until they resulted in clear solutions. For the PPGbased formulation, cordycepin was dissolved in PPG at a concentration of 13.0 mg/mL, and the formulation was then sonicated in a water bath for 15 min. After confirming that the formulation was a clear solution, deionised-distilled water (DDW) was added to the formulation to give a final concentration of 10.0 mg/mL. This resulted in a PPG-based formulation with a composition of PPG/DDW = 77:23.
Formulation Stability Test
Formulations of cordycepin prepared as described above were tested for their stability at four different storage conditions: −80, −20 and 4°C and room temperature. Prepared formulations were aliquoted into 1.5-mL centrifuge tubes and were stored under different conditions. Three samples of each storage condition were withdrawn after 4 and 11 days or 3, 8 and 12 weeks after preparation to assess the stability of the formulations.
Filter Sterilisation
PBS-based formulations of cordycepin were filtersterilised using Sartorius Minisart syringe filters (polyethersulfone, 0.2-μm pore size). Aliquots (700 μL) of the formulations prepared as described above were filtered through the devices, and air was purged using a 1-mL syringe. Concentrations of cordycepin in the formulations were measured before and after the filter sterilisation procedure. The evaluation was performed in quadruplicate.
Analytical Method
Analysis of cordycepin concentrations in the samples was performed using a HPLC-UV system consisting of a Waters Alliance 2695 separation module equipped with a Waters 996 photodiode array detector. The autosampler temperature was maintained at 10°C, and the column temperature was set at 40°C. The stationary phase was a Capcell Pak C18 4.6 × 150 mm, 3-μm particle size column (Shiseido, Tokyo, Japan), protected by a SecurityGuard 2 × 4 mm, 3-μm particle size column (Phenomenex, Macclesfield, UK). The mobile phase was an isocratic composition of acetonitrile/DDW at a ratio of 6:94 (v/v). The flow rate of the mobile phase was 0.8 mL/min, and the chromatograms were monitored at a wavelength of 259 nm. The injection volume was 40 μL.
Sample Preparation
For HPLC-UV sample preparation, formulation samples were firstly diluted with DDW to yield 1.0 mg/mL of cordycepin (dilution ratios were 18.2:81.8, 22.2:77.8, 33.3:66.7 and 10:90 for formulations of PBS pH 4.0, PBS pH 4.5, PBS pH 5.0 and PPG-based formulation, respectively). From these diluted samples, 10 μL was withdrawn and added to 980 μL of DDW with 10 μL of internal standard stock solution (1.0 mg/mL adenosine in DDW). The samples were then vortex mixed, and 100 μL aliquots were transferred to HPLC vials for analysis.
Calibration curve samples were prepared with working standard solutions of cordycepin (in DDW) at concentrations of 5, 10, 25, 50, 100, 250, 500 and 1000 μg/mL. DDW-based diluents were prepared to match the composition of each formulation sample medium (0.187% PBS pH 4.0, 0.227% PBS pH 4.5, 0.344% PBS pH 5.0 and 0.079% PPG). Samples were prepared by adding 20 μL of the cordycepin working standard solutions to 970 μL of the DDW-based diluents with 10 μL of internal standard stock solution (1.0 mg/mL adenosine in DDW). The resulting calibration curve points were 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 μg/mL. The samples were then vortex mixed, and 100 μL aliquots were transferred to HPLC vials. 
Validation of the Analytical Method
Validation of the analytical method was performed for accuracy and precision. Accuracy was expressed as relative error (RE), which represents the bias from nominal concentrations. Precision was expressed as relative standard deviation (RSD), which represents the coefficient of variation at each concentration level [46, 47] . Both accuracy and precision were assessed by intra-day (six replicates in 1 day) and inter-day (replicates on six different days) variability. The concentration levels of quality control (QC) samples were the lower limit of quantification (LLOQ, 0.1 μg/mL), low QC (LQC, 0.25 μg/mL), medium QC (MQC, 1.5 μg/mL) and high QC (HQC, 15 μg/mL). The QC samples were prepared in the same manner as calibration curve samples in each formulation sample medium.
Statistical Analysis
All data were expressed as mean ± standard deviation (SD). Statistically significant differences between measurements in different media were assessed using the unpaired two-tailed t test. The differences between measurements in one sample before and after sterilisation were assessed using the paired two-tailed t test. Statistical significance was declared when p < 0.05.
RESULTS
Prior to formulation development, the maximal solubility of cordycepin in water for injection, normal saline, PBS at three different pH levels (4.0, 4.5 and 5.5) and PPG was assessed. The results are shown in Fig. 1 . The use of PBS at pH 4.0 and PPG resulted in significantly higher solubility of cordycepin compared to water or normal saline (both p < 0.001). Following the solubility results, formulations were developed in each medium at concentrations lower than the maximal solubility in the respective medium (Table II) . The PBS-based formulations were intended for intravenous and oral administration, while the PPG-based formulation was developed for higher dose oral administration. The achievable dose for each route of administration was calculated based on recommendation from a previous report [42, 43] . The analytical method used for the stability assessment of the formulations was fully validated by intra-day and interday validation in order to evaluate the reliability of the method. The results in Table III show that the method has acceptable precision and accuracy at all QC levels tested. Representative chromatograms from the analytical method are shown in Fig. 2 .
Stability of the formulations was assessed under four different storage conditions (−80, −20 and 4°C and room temperature) up to 3 months for PBS-based formulations and up to 3 weeks for PPG-based formulations. The results in Table IV show that all PBS-based formulations were stable at −80 and −20°C and at room temperature for up to 3 months. Interestingly, crystallisation of cordycepin was observed in samples stored at 4°C in PBS-based formulations. The rate of crystallisation differed with pH of the formulations, as crystallisation at pH 4.0 and at pH 4.5 in PBS was found after 6 days but at pH 5.0 in PBS only after 11 days. The PPG-based formulation was stable under all four storage conditions up to 3 months, and crystallisation was not observed in any of the samples.
The feasibility of simple filter sterilisation of the PBSbased formulations was assessed by measuring the concentration of cordycepin before and after filtration. The results in Table V show that there was no statistically significant loss during the filter sterilisation (p > 0.05). Therefore, filter sterilisation can be applied without RT room temperature compromising the concentration of the PBS-based formulations.
DISCUSSION
Knowledge of the maximal solubility of cordycepin in various dosing vehicles is essential information for the development of solution phase-based formulations. Some preclinical studies listed in Table I used concentrations that in fact exceed the maximal solubility of cordycepin in the respective dosing vehicles. Therefore, it is likely that the formulations used in these studies were in a suspension state. As previously mentioned, suspension-based formulations could complicate the interpretation of the results due to dissolution-related factors involved following oral or intraperitoneal administration. Intravenous administration of heterogeneous suspensions can also a cause adverse effects.
PBS is an isotonic vehicle that causes minimal discomfort when administered intravenously or orally. The solubility of cordycepin in PBS was highest at pH 4.0, probably due to the fact that cordycepin is a weak base (pK a = 3.6, predicted by ACD/Labs, Toronto, Canada). Decreasing the pH further would likely result in even higher solubility. However, the recommended pH range for intravenous formulations is 4-9, and therefore, the lowest pH tested in this work was 4.0 [42] .
A PPG-based formulation was developed in order to enable higher doses of cordycepin to be delivered by the oral route. PPG is a widely used and a well-tolerated dosing vehicle in preclinical studies. A previous study reported that oral administration of as much as 1000 mg/ kg/day of PPG for 90 days was tolerable in rats [48] . The solubility of cordycepin in PPG was 2.7-fold higher than in pH 4.0 PBS (Fig. 1) . However, pure PPG as a dosing vehicle can present difficulties in practical use during preclinical experiments due to its high viscosity. Therefore, PPG was diluted with DDW to produce the final formulation. As a result, our PPG-based formulation is composed of PPG/DDW = 77:23 at 10 mg/mL cordycepin, and addition of water did not cause any precipitation of cordycepin in this formulation.
The analytical method used in this study was developed based on a previous report where cordycepin was analysed in extracts of Cordyceps using HPLC-UV methods [49] . However, this previously reported analytical method was limited by the fact that an internal standard was not used and validation results were not provided. Therefore, in the present study, we incorporated an internal standard to improve the precision and accuracy of the method, and we also performed a full validation of the method (Table III) . This HPLC-UV method could provide useful information for future studies where concentrations of cordycepin are to be analysed in other formulations.
Formulations intended for intravenous administration should not only be free of particles but should also be aseptic [42] . In this study, filter sterilisation was tested for its feasibility, as it is one of the techniques that do not require heating of the formulation. One concern for filter sterilisation can be that the drug might have non-specific binding to the filter or the device. The results in our case showed that the PBS-based cordycepin formulations can be filter-sterilised without affecting the concentration of the formulations (Table V) .
Surprisingly, and rather counterintuitively, we observed that a temperature of 4°C is the only storage condition to be avoided for PBS-based formulations. This is probably because the slow cooling process provided upon storage at 4°C resulted in crystallisation of cordycepin. It is often reasonable to assume that pharmaceutical formulations are more stable at lower temperatures [50] . Moreover, when a label instructs to store a drug below a certain temperature (e.g. Bstore below 25°C^), this usually means that storage in the fridge would provide stable conditions [51] . However, the current study emphasises that storage of the formulations or dosage forms at lower temperature might in fact result in poorer stability from a physical point of view.
CONCLUSION
Herein, we report a study where simple and readily applicable formulations of cordycepin were developed and tested for their stability. An HPLC-UV method for quantification of cordycepin in the formulations was developed and validated. Additionally, the PBS-based formulations could be sterilised by filtration without loss of material. The PBS-based formulations were stable for up to 3 months at room temperature, −20 and −80°C but not at 4°C, which suggests, rather counterintuitively, that storage of the formulations or dosage forms at lower temperature might in fact result in poorer physical stability. This study could provide useful information for future preclinical and clinical studies with cordycepin. 
